20:35:05 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-06-06 Ordinarie utdelning CRNA 0.00 NOK
2024-06-05 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-04 Split CRNA 30:1
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-22 Årsstämma 2023
2023-04-21 Ordinarie utdelning CRNA 0.00 NOK
2023-03-09 Extra Bolagsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-20 Årsstämma 2022
2022-04-07 Ordinarie utdelning CRNA 0.00 NOK
2022-02-17 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning CRNA 0.00 NOK
2021-03-17 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 Ordinarie utdelning CRNA 0.00 NOK
2020-04-29 Årsstämma 2020
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning CRNA 0.00 NOK
2019-04-09 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning CRNA 0.00 NOK
2018-04-11 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning CRNA 0.00 NOK
2016-04-13 Årsstämma 2016
2015-06-23 Ordinarie utdelning CRNA 0.00 NOK
2015-06-22 Årsstämma 2015

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Circio Holding är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Lysaker.
2023-03-02 13:15:27
Oslo, 2 March 2023: The board of directors of Targovax ASA (OSE:TRVX)
("Targovax" or the "Company") has resolved to increase the share capital of the
Company following the completion of a settlement period for vested restricted
stock units ("RSUs"). The settlement period commenced on 24 February 2023 at
10:00 hours (CEST) and ended on 2 March 2023 at 12:00 hours (CEST).

1. Settlement of RSUs

The board members Diane Mellett, Robert Burns, Damian Marron and Eva-Lotta Allan
have settled 20,870, 23,307, 55,588 and 4,024 RSUs, respectively. Hence in
total, 103,789 RSUs were settled, giving the RSUs holders the right to subscribe
for 103,789 new shares in total, each with a par value of NOK 0.10, at a
subscription price of NOK 0.10 per share.

The RSU holders have previously elected to receive the RSUs as part of their
board remuneration instead of cash payment pursuant to resolutions by the annual
general meeting (the "AGM") of the Company. The number of RSUs granted was
calculated as the NOK amount of the RSU selected portion of the total
remuneration to the respective board member, divided by the market price for the
shares, calculated as the volume weighted average share price for the 10 trading
days prior to the relevant AGM, being NOK 6.34 per share in 2019, NOK 6.81 per
share in 2020, NOK 8.80 per share in 2021 and NOK 1.79 per share in 2022.

2. Resolution to increase the share capital in Targovax ASA

The board of directors of the Company has today, on 2 March 2023, in accordance
with the authorisation granted by the general meeting on 20 April 2022, resolved
to increase the share capital of the Company with NOK 10,378.90  by issuance of
103,789 new shares, each with a par value of NOK 0.10, in order to facilitate
the settlement of RSUs, as further described above.

The new share capital of the Company will be NOK 18,857,757.20, divided into
188,577,572 shares, each with a par value of NOK 0.10. The share capital
increase will be registered with the Norwegian Register of Business Enterprises
(Nw. Foretaksregisteret) as soon as practically possible.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and to bring benefit to
cancer patients with few available treatment alternatives. Targovax is
developing its product candidates in different cancer indications, including
melanoma, mesothelioma, multiple myeloma and pancreatic cancer.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. ONCOS-102 has
demonstrated a favorable efficacy, immunological and safety profile in several
indications, both as monotherapy and in combinations, and ONCOS-102 is
progressing into a randomized phase 2 trial in melanoma patients resistant to PD
-1 checkpoint inhibitor treatment.

Targovax has also established a cutting-edge circular RNA (circRNA) program with
the intent to develop next generation RNA therapeutics for various applications,
building on clinical experience and deep mechanistic insights from its first
generation products.  In addition, Targovax has a KRAS immunotherapy program,
with lead candidate TG01 due to enter clinical trials in an enhanced format in
pancreatic cancer and multiple myeloma during early 2023. This provides Targovax
with a rich pipeline of innovative future therapeutic candidates to follow ONCOS
-102.